This proposal is from an inter-disciplinary team with expertise in imaging, systems biology and clinical research (Weissleder, Sorger, Mitchison and Danuser). It responds to RFA-CA-11-005, and proposes to create and validate a platform for quantitative cancer pharmacology in mice using live imaging at the single-cell level. The immediate goal is to determine how individual cancer cells in tumors respond to single and dual-agent therapy in vivo by measuring both the uptake and distribution of drugs in tumor cells (pharmaco-kinetics, PK), as well as the multiple downstream responses that play out over different time-scales (pharmaco-dynamics, PD). Our focus will be on the use of navitoclax (ABT263;an investigational antagonist of Bcl-2 and Bcl-Xl) and gemcitabine (a well established, S-phase-specific cytotoxic drug), both individually and in combination.
Aim 1 will develop and validate live-cell biosensors for measuring pre-drug tumor states and drug responses in mouse xenograft tumors by sub-cellular resolution intravital imaging.
Aim 2 will develop injectable imaging agents based on novel bioorthogonal chemistries that will be used to label drugs fluorescently or with 18F. These agents will then be validated using the biosensors from aim 1.
Aim 3 will focus on the development of computational methods for extracting quantitative data from intravital images, and on the creation of data- driven, multi-scale (PK/PD;single cell kinetics and mechanistic/molecular) mathematical models that elucidate therapeutically relevant differences between mono and combination therapy. Overall, our goal is to gain an understanding of drug action that is: a) quantitative (in the treatment of data that may vary in time and space);b) probabilistic (accounting for cell-to-cell and tumor-to-tumor variability);c) mechanistic at the molecular level;d) post-genomic (analyzing diverse cell lines and patient samples with known genetic differences);e) integrative (assuming that determinants of drug response are multi-factorial);f) mathematically sophisticated (with respect to mass-action, lumped parameter and stochastic modeling);and g) medically relevant (by analyzing a combination therapy currently under clinical investigation and by developing translatable measurement methods). Success of the project will result in an integrated platform for single-cell cancer pharmacology. This platform will not only serve to overcome prevailing impediments to the translation of preclinical results into a clinical setting, but will provide the knowledge base for rational and predictive combination therapy. Likewise, it will improve our ability to develop effective drugs capable of inhibiting new and existing targets, and could also be more broadly used in the development of other emerging anti-cancer drugs.

Public Health Relevance

The central goal of this multi-investigator application is to develop novel theoretical concepts, approaches and advanced imaging technologies to gain in-depth, systems level knowledge of how biological molecules, proteins and cells interact during cancer treatment. The proposed studies will continue to push the research frontier and will lead to new clinical strategies to combat cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA164448-03
Application #
8517457
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (O1))
Program Officer
Menkens, Anne E
Project Start
2011-09-21
Project End
2016-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
3
Fiscal Year
2013
Total Cost
$760,040
Indirect Cost
$155,276
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Miller, Miles A; Askevold, Bjorn; Yang, Katherine S et al. (2014) Platinum compounds for high-resolution in vivo cancer imaging. ChemMedChem 9:1131-5
Laughney, Ashley M; Kim, Eunha; Sprachman, Melissa M et al. (2014) Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. Sci Transl Med 6:261ra152
Kim, Eunha; Yang, Katherine S; Giedt, Randy J et al. (2014) Red Si-rhodamine drug conjugates enable imaging in GFP cells. Chem Commun (Camb) 50:4504-7
Lee, Sungon; Vinegoni, Claudio; Sebas, Matthew et al. (2014) Automated motion artifact removal for intravital microscopy, without a priori information. Sci Rep 4:4507
Dubach, J M; Vinegoni, C; Mazitschek, R et al. (2014) In vivo imaging of specific drug-target binding at subcellular resolution. Nat Commun 5:3946
Turetsky, Anna; Kim, Eunha; Kohler, Rainer H et al. (2014) Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor. Sci Rep 4:4782
Dubach, J Matthew; Vinegoni, Claudio; Weissleder, Ralph (2014) Steady state anisotropy two-photon microscopy resolves multiple, spectrally similar fluorophores, enabling in vivo multilabel imaging. Opt Lett 39:4482-5
Thurber, Greg M; Reiner, Thomas; Yang, Katherine S et al. (2014) Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer Ther 13:986-95
Thurber, Greg M; Yang, Katy S; Reiner, Thomas et al. (2013) Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun 4:1504
Coffey, Sarah Earley; Giedt, Randy J; Weissleder, Ralph (2013) Automated analysis of clonal cancer cells by intravital imaging. Intravital 2:

Showing the most recent 10 out of 15 publications